Global Blood Therapeutics Inc. (GBT)

44.40
1.30 3.00
NASDAQ : Health Technology
Prev Close 43.10
Open 43.25
Day Low/High 41.70 / 45.55
52 Wk Low/High 24.02 / 68.05
Volume 459.54K
Avg Volume 873.00K
Exchange NASDAQ
Shares Outstanding 50.73M
Market Cap 2.22B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GUERBET : 2017 Annual Results

GUERBET : 2017 Annual Results

5 Stocks That Are Showing Signs of Reversing

5 Stocks That Are Showing Signs of Reversing

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

GBT Appoints Industry Leader David L. Johnson As Chief Commercial Officer

GBT Appoints Industry Leader David L. Johnson As Chief Commercial Officer

Appointment Strengthens Management Team as Company Advances Clinical Development of Voxelotor, a Potential Disease-Modifying Therapy for Sickle Cell Disease

With an Eye on Biotech, Here's Today's Trading Thesis

With an Eye on Biotech, Here's Today's Trading Thesis

It is important to note that watching for a reversal is much different than being short.

The Confidence in the Dip Buyers Has Weakened

The Confidence in the Dip Buyers Has Weakened

The bears are likely to be increasingly bold if there's a failed bounce.

This Market Badly Needs a Rest

This Market Badly Needs a Rest

It would be a longer-term positive if the overbought conditions are alleviated.

The Stock Market Is Facing One Big Obstacle Right Now

The Stock Market Is Facing One Big Obstacle Right Now

You have to wonder how much longer we can run without a pullback of at least 2%.

Selling Action Is Upon Us

Selling Action Is Upon Us

There is still a very strong appetite for individual stocks with momentum.

Notable Tuesday Option Activity: GBT, SFM, CROX

Notable Tuesday Option Activity: GBT, SFM, CROX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Global Blood Therapeutics Inc , where a total volume of 6,399 contracts has been traded thus far today, a contract volume which is representative of approximately 639,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.1% of GBT's average daily trading volume over the past month, of 1.5 million shares.

GBT Receives FDA Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease (SCD)

GBT Receives FDA Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease (SCD)

Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation

First Week Of GBT February 2018 Options Trading

First Week Of GBT February 2018 Options Trading

Investors in Global Blood Therapeutics Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GBT options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

GBT Announces New Phase 2a Data At ASH For Voxelotor In Adolescents With Sickle Cell Disease (SCD)

GBT Announces New Phase 2a Data At ASH For Voxelotor In Adolescents With Sickle Cell Disease (SCD)

Data to be Highlighted in ASH Press Briefing and Company to Host Investor Webcast on Monday, December 11, at 8:15 p.m. ET/5:15 p.m. PT to Discuss Data